Stay updated with breaking news from Morphogenesis Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- According to Coherent Market Insights, the global veterinary oncology market is estimated to be valued at US$ 592.8 million in 2022 and is...
/PRNewswire/ -- According to Coherent Market Insights, the global veterinary oncology market is estimated to be valued at US$ 592.8 million in 2022 and is...
Search jobs 22-Feb-2021 Veterinary Vaccine Market will grow at 6.2% CAGR, to be valued at US$ 11,627.46 Million by 2027 Impact Analysis of Covid-19 The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters. , by Technology (Inactivated Vaccines, Toxoid Vaccines, Live Attenuated Vaccines, and Subunit and DNA Vaccines), By Animal Type (Companion (Equine, Canine, and Feline) and Livest...
Updated: 11:22 AM EST January 28, 2021 TAMPA, Fla — A skin cancer vaccine developed by a local Tampa company will soon begin "phase one" of its clinical trials. Morphogenesis, Inc. says it will soon open the trial to local and regional dermatology clinics already experienced with clinical trials. This trial will treat patients who have been "just diagnosed" with skin cancers, such as melanoma, basal cell carcinoma or cutaneous squamous cell carcinoma, the company says. Early stage skin cancers such as these are usually treated surgically, according to Morphogenesis. With...